For example, through the analysis of nine gene promoters, Hoque et al. found that 69% of bladder cancer patients had methylation in at least one of four genes (CDKN2A, ARF, MGMT and GSTP1), whereas the control patients had no such methylation detectable [28]. This evidence concerns the gene GSTP1 and urinary bladder carcinoma.